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ABSTRACT
Objective People with multiple sclerosis (MS) have
difﬁculties with decision-making but it is unclear if this is
due to changes in impulsivity, risk taking, deliberation or
risk adjustment, and how this relates to brain pathology.
Methods We assessed these aspects of decision-
making in 105 people with MS and 43 healthy controls.
We used a novel diffusion MRI method, diffusion
orientational complexity (DOC), as an index of grey
matter pathology in regions associated with decision-
making and also measured grey matter tissue volumes
and white matter lesion volumes.
Results People with MS showed less adjustment to risk
and slower decision-making than controls. Moreover,
impaired decision-making correlated with reduced
executive function, memory and processing speed.
Decision-making impairments were most prevalent in
people with secondary progressive MS. They were seen
in patients with cognitive impairment and those without
cognitive impairment. On diffusion MRI, people with MS
showed DOC changes in all regions except the occipital
cortex, relative to controls. Risk adjustment correlated
with DOC in the hippocampi and deliberation time with
DOC in the medial prefrontal, middle frontal gyrus,
anterior cingulate and caudate parcellations and with
white matter lesion volumes.
Conclusions These data clarify the features of
decision-making deﬁcits in MS, and provide the ﬁrst
evidence that they relate to grey and white matter
abnormalities seen using MRI.
INTRODUCTION
Impaired decision-making is seen in people with
relapsing–remitting (RR)1 2 and progressive forms
of multiple sclerosis (MS).3 It may be detected in
the early stages of the disease,2 and is known to
deteriorate over time.4 Impaired decision-making is
of clinical relevance as it impacts on treatment
compliance,5 employment6 and function in every-
day life.1 However, it is unclear exactly which com-
ponents of decision-making are most affected, and
whether or not these differ between MS subtypes.
Effective decision-making requires processing
information, forming preferences, selecting and
executing actions and assessing outcomes. Impaired
decision-making can therefore reﬂect a variety of
problems, including difﬁculties in assessing out-
comes, increased impulsivity and poor adjustment
to risk. MS studies have used the Iowa Gambling
Task,7 a test providing a general measure of
decision-making, but not of its separate compo-
nents. Abnormal performance in different neuro-
logical populations has been variously linked to
impairments in working memory,8 risk taking9 or
emotional response to feedback.10 MS studies using
the Iowa Gambling Task have not found correla-
tions with performance on tests of executive func-
tion, working memory or processing speed,1 2 11
and it has been suggested that impaired decision-
making may reﬂect poor learning of outcomes2 or
mood-disturbance.4 It remains to be determined
whether impulsivity and poor adjustment to risk
also play a role in MS. No associations have been
reported between impaired decision-making and
MRI abnormalities in MS, and the contributions of
grey matter (GM) and white matter (WM) path-
ology remain to be determined. In this study, we
used the Cambridge Gambling Task (CGT,12) to
assess decision-making. As opposed to the Iowa
Gambling Task, which relies on implicit learning of
outcomes, the CGT gives participants explicit infor-
mation about outcome probabilities (ﬁgure 1). In
doing so, it can independently measure impulsivity,
risk taking, deliberation and risk adjustment.
Functional MRI studies in healthy adults demon-
strate that networks involved in decision-making
are widespread, including dorsolateral and medial
prefrontal cortices,13 the hippocampus14 and stri-
atum.15 Neuropsychological studies also highlight
the role of prefrontal cortices and the striatum in
decision-making, with impairments observed fol-
lowing lesions to the ventromedial prefrontal
cortex16 17 and in those with conditions affecting
frontostriatal circuits, such as Parkinson’s disease
and Huntington’s disease.18 However, to the best
of our knowledge, the structural substrates of
decision-making deﬁcits in MS have not been
investigated.
In this study we addressed four questions: First,
which aspects of decision-making are impaired in
MS? Second, does the pattern or impairment differ
between MS subtypes? Third, is impaired decision-
making related to disease duration? Fourth, is
decision-making impairment related to GM and
WM abnormalities? Changes in GM structures
associated with decision-making can be assessed
using measures of volume loss (ie, atrophy) and dif-
fusion MRI changes. To assess diffusion changes in
GM we used a recently developed measure, diffu-
sion orientational complexity (DOC). DOC uses a
bootstrap approach to analyse diffusion data and
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was used for two reasons. First, unlike in WM, the distribution
of diffusion in GM is not normally distributed (ie, Gaussian).
Whereas a critical assumption of the diffusion tensor model is
that a normal distribution in diffusion exists (which makes it
suitable for WM voxels), DOC does not rely on this assump-
tion. Second, it has previously been shown that DOC in GM
has stronger associations with executive function impairment in
people with MS than conventional diffusion tensor imaging
measures in the same regions.19
MATERIALS AND METHODS
Participants
We recruited 105 participants with MS (61 RR, 26 secondary
progressive (SP) and 18 primary progressive (PP)) who had not
experienced a relapse or received corticosteroids within the pre-
ceding 4 weeks (table 1). Their median Expanded Disability
Status Scale (EDSS) score was 5 (range 0–8.5) and their mean
disease duration was 14.9 years (range 1–45 years). We also
examined 43 healthy volunteers with no known neurological or
psychiatric disorders. MS subtypes were classiﬁed as per Lublin
and Reingold criteria.20 We obtained written informed consent.
Clinical assessment
Cognitive assessment was conducted by an experienced neuro-
psychologist usually on the same day as scanning. Full details of
the cognitive battery and CGT are presented in the online sup-
plementary material. Brieﬂy, in the CGT a token is randomly
hidden in 1 of 10 boxes. The boxes are either red or blue, and
the proportion of each varies between trials. The participant is
asked to predict which colour box contains the token, and
gamble points on this. For each trial the amount bet automatic-
ally increases or decreases with time until a decision is made.
The results of the CGT are broken down into: (1) rational-
choices, the proportion of trials in which the participant
chooses the likely outcome; (2) deliberation time; (3) amount
bet; (4) impulsivity index, the difference in percentage bet in
ascending and descending conditions (consistent early bets
produce a high impulsivity index); and (5) risk-adjustment
index, the adjustment of bets to match the odds.
Patients were classiﬁed as cognitively impaired if they scored
1.96 SDs below the mean of the controls (ie, at the p<0.05
level) on two or more cognitive tests (Hayling overall, Stroop B
time, Story memory immediate recall, Story memory delayed
recall, Figure recall immediate, Figure recall delayed, symbol
digit modalities test). Working memory, as measured using the
Wechsler Adult Intelligence Scale-III (WAIS-III) digit span test,
was also assessed and compared between the cognitively
impaired people with MS, those who were cognitively unim-
paired and healthy controls.
EDSS21 scores were determined for patients.
MRI sequences
MRI data were acquired to look for associations between struc-
tural brain abnormalities and decision-making deﬁcits. Based on
previous work, DOC derived from diffusion imaging19 was used
to look for microstructural GM tissue changes and volumetric
imaging to look for tissue atrophy, both of which may be asso-
ciated with cognitive deﬁcits.
High angular resolution diffusion imaging (HARDI) scans
were obtained using a cardiac-gated spin-echo echo-planar
sequence acquired axial-oblique and aligned with the anterior
commissure (AC)-posterior commissure (PC) line (2 mm×2
mm×2 mm, 61 isotropically distributed diffusion-weighted
directions with b=1200 s/mm2, 7 non-diffusion-weighted (b=0)
volumes, TE=68 ms, TR ∼24 s (depending on cardiac rate),
SENSE factor=3.1). Dual-echo proton density/T2-weighted
axial-oblique scans aligned with the AC-PC line (1 mm×1 mm×
3 mm, TR=3500 ms, TE=19/85 ms) and 3D sagittal
T1-weighted fast ﬁeld echo (FFE) scans (1 mm×1 mm×1 mm,
TR=6.9 ms, TE=3.1 ms) were also acquired.
The HARDI scans were processed in native participant space.
For each participant the T1-weighted FFE scan was registered to
the HARDI data set (see online supplementary material). All
registrations (except eddy-current correction) were carried out
using NiftyReg (http://sourceforge.net/projects/niftyreg22). An
experienced rater (VS) determined whole brain WM lesion
volumes on the PD/T2-weighted scans using a semiautomated
tool in JIM V.6.0 (Xinapse Systems, Leicester, UK).
Generation of DOC, FA and MD, as well as GM parcellations
and registrations were carried out as described earlier.19
Figure 1 A screenshot from the Cambridge Gambling Task (CGT). In
the CGT a token is randomly placed in 1 of 10 coloured boxes. The
boxes are either red or blue, and the proportion of each varies between
trials. The participant is asked to predict which colour box contains the
token, and gamble points on this. For each trial, the amount bet
automatically increases or decreases with time until a decision is made.
Table 1 Demographics of the participants. Values are mean (SDs) unless otherwise stated
Controls All MS RR SP PP
N 43 105 61 26 18
Age (mean [SD]) 41.9 (13.1) 45.9 (10.4) 42.0 (9.6) 52.3 (8.0)** 50.2 (10.4)*
Gender (female:male) 25:18 67:38 40:21 16:10 11:7
Duration of MS from first clinical event (mean) – 14.9 (9.6) 12.1 (8.2) 23.7 (9.0) 11.7 (7.0)
EDSS (median [range]) – 5 (0–8.5) 2 (0–7.5) 6.5 (4.5–8.5) 6 (1.5–6.5)
*p<0.05, **p<0.01, ***p<0.001 (comparisons are for the whole MS group against healthy controls or MS clinical subgroups against healthy controls).
EDSS, expanded disease severity scale; MS, multiple sclerosis; PP, primary progressive; RR, relapsing-remitting.
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On the basis of previous decision-making studies,13–15 23 a set
of a priori parcellations (medial prefrontal cortex, middle
frontal gyrus (ie, dorsolateral prefrontal cortex), anterior cingu-
late, hippocampus and caudate) from the Harvard-Oxford
atlas24 were transformed into native diffusion space and masked
with GM tissue masks. These parcellations were chosen a priori
given their well-known involvement in decision-making and to
average MRI values across anatomical features, in line with pre-
vious studies.23 Regional speciﬁcity was assessed by examining
changes in the occipital pole, a region where pathology would
be unlikely to contribute to decision-making. Mean diffusion-
based measurements were extracted from left-sided and right-
sided parcellations and mean scores across both were used, as
previous studies in people with traumatic brain injury23 report
impaired CGT performance related to bilateral diffusion
abnormalities.
GM volume within each parcellation (in native T1 space) was
measured using SPM8 tissue maps binarised with an in-house
maximum likelihood algorithm. Total intracranial volume was
quantiﬁed by summing the GM, WM and CSF volumes from
the binarised whole brain tissue maps. The study did not aim to
investigate regional cortical atrophy, but at detecting the subtle
regional GM abnormalities using DOC. However, using the
measure of GM volume in the same parcellation allowed us to
control for the possible effects of brain atrophy.
In additional work, using the diffusion mean FA and MD
values within each GM parcellation were also measured using
previously described measures (see online supplementary
material).19
Statistical analysis
Group differences in demographics, clinical scores and decision-
making measures were tested between controls and people with
MS using unpaired t tests and χ2 tests, as appropriate. All data
were checked for normality on skewness and kurtosis measures.
Non-normally distributed data was analysed using Spearman
correlations or Mann-Whitney tests, as appropriate. An execu-
tive function z-score was produced by averaging z-scores on the
Hayling and Stroop tests (in each case based on the number of
SDs from the mean of controls). Processing speed was measured
using the symbol-digit modalities test (SDMT;25), for which
z-scores were obtained with reference to published norms.26
Immediate and delayed memory was assessed using the story
recall (verbal memory) and ﬁgure recall (visual memory) from
the adult memory and information processing battery.27
A memory function z-score was produced by averaging z-scores
on the immediate and delayed visual and verbal memory tests
(based on the number of SDs from the mean of the controls).
Pearson correlations assessed associations between decision-
making components and either executive function, memory or
processing speed in people with MS alone, and in controls
alone (correcting for the three correlations using Bonferroni’s
method, ie, α levels of 0.017. Correlations with p values that
fall between 0.05 and this value are considered non-signiﬁcant
trends). Participants were classiﬁed as being impaired on a given
decision-making component if they scored >1.96 SDs (ie, at the
p<0.05 level) below the control mean. Differences in decision-
making on each component were further assessed between clin-
ical subgroups using a multivariate analysis of variance
(MANOVA) with clinical subgroups as independent variable.
Signiﬁcant differences were followed up using post hoc Tukey’s
tests to assess differences between pairs of groups.
Differences in diffusion and volumetric MRI measures
between groups were initially assessed using unpaired t tests
(corrected for multiple comparisons). For diffusion MRI mea-
sures, univariate analyses of covariance covarying for GM
volume within a given parcellation was also undertaken. Pearson
correlations were assessed between decision-making components
that were impaired in people with MS and the diffusion-based
and volumetric measures in each of the cortical parcellations
(correcting for the ﬁve parcellations of interest using
Bonferroni’s method, ie, α values of 0.01; correlations with p
values that fall between 0.05 and this value are considered non-
signiﬁcant trends), as well as with T2 lesion volumes. Linear
regressions assessed whether decision-making components were
best predicted by DOC or GM volume normalised to total intra-
cranial volume (ie, atrophy). SPSS V.21 was used for all statistical
analyses.
Comparisons between DOC and conventional DTI measures
are given in the online supplementary material.
RESULTS
Demographics and cognitive performance
The MS group did not differ from controls in their estimated
premorbid IQ (p=0.19), but showed lower verbal (p<0.001),
performance (p<0.001) and full scale (p<0.001) IQ than con-
trols (table 2). The MS group had slower processing speed than
controls on the SDMT (p<0.001) and worse executive function
(Hayling, p=0.005; Stroop, p<0.001). On tests of memory, the
MS group showed worse immediate (p<0.001) and delayed
(p<0.001) story recall, and worse immediate (p<0.001) and
delayed (p<0.001) ﬁgure recall, relative to controls. Patients had
signiﬁcantly lower scores than controls on the executive function
z-score (p<0.001) and memory function z-score (p<0.001). On
the Hospital Anxiety and Depression Scale (HADS), the MS
group showed signiﬁcantly higher scores than controls for
depression (p<0.001), but not anxiety (p=0.37). Thirty patients
were classiﬁed as cognitively impaired and 75 as unimpaired. In
the control group only 3 of 40 participants were classiﬁed as cog-
nitively impaired. Cognitively impaired patients showed signiﬁ-
cantly worse working memory on the digit-span test than healthy
controls (p<0.01), but there were no signiﬁcant differences
between those who were cognitively unimpaired and healthy
controls (p=0.23).
Decision-making in people with MS and controls
The MS group had longer deliberation times (p=0.002) and
worse risk adjustment (p=0.003) than controls, but there were
no signiﬁcant group differences on amount bet, impulsivity or
rational-choice components. Similar ﬁndings were observed
when comparing cognitively impaired patients to controls and
those who were cognitively unimpaired to controls, with slower
deliberation (p<0.001 and 0.040, respectively) and worse risk
adjustment (p<0.001 and 0.020, respectively). In addition,
those with MS who were cognitively impaired performed worse
on the rational-choice component than controls (p=0.037).
Impairment on one or more CGT components was seen in 30%
(31/105) of patients and 12% (5/43) of controls. Impairment on
one or more CGT components was more common in SPMS
(46%, 12/26) than controls (χ2 test, p=0.001), but did not sig-
niﬁcantly differ between controls and RR (23%, 14/61) or PP
28% (5/18) patients (p=0.14 and p=0.12, respectively), or
between the MS subtypes. Age was not signiﬁcantly correlated
with any decision-making component in people with MS or con-
trols. The group differences in decision-making remained signiﬁ-
cant after controlling for age and gender.
In the MS group, the executive function z-score correlated
with rational-choices (r=0.28, p=0.005), deliberation time (r=
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−0.32; p=0.002), and showed a non-signiﬁcant trend for an
association with risk-adjustment scores (r=0.23, p=0.02).
Similarly, memory z-scores correlated with deliberation time (r=
−0.31, p=0.003), amount bet (r=−0.26, p=0.01) and
risk-adjustment scores (r=0.40, p<0.001), and showed a non-
signiﬁcant trend for an association with rational-choices
(r=0.21, p=0.04). Information processing speed on the SDMT
correlated with deliberation time (r=−0.37, p<0.001), and
showed non-signiﬁcant trends for associations with amount bet
(r=−0.20, p=0.04) and risk-adjustment (r=0.23, p=0.02).
Higher anxiety scores correlated with lower rational-choices
scores (r=−0.20, p=0.04; ie, participants choosing the majority
colour less often) but there were no other signiﬁcant correla-
tions between mood and decision-making). In those with MS,
repeating the decision-making-cognition correlations after con-
trolling for levels of anxiety (ie, partial correlations) did not
affect the associations with risk adjustment or deliberation but
the correlations between amount bet and memory and executive
function were, however, no longer signiﬁcant. In controls, risk
adjustment correlated with memory z-scores (r=0.53,
p<0.001), executive function z-scores (r=0.42, p=0.005) and
processing speed on the SDMT (r=0.46, p=0.002). There were
no other signiﬁcant correlations between decision-making com-
ponents and cognitive measures in controls.
Decision-making in different MS subtypes
The MANOVA revealed signiﬁcant group differences in deliber-
ation (p=0.001) and risk adjustment (p=0.008) but not in
rational-choices, amount bet or impulsivity scores (table 3). Post
hoc Tukey’s tests showed signiﬁcantly slower deliberation times
in SPMS than controls (corrected p<0.001) and patients with
RRMS (corrected p=0.042). Risk adjustment was signiﬁcantly
worse in SPMS than controls (corrected p=0.007) and a similar
trend was present in patients with RRMS (corrected p=0.06).
In the whole MS group, only deliberation time correlated with
duration of disease (r=0.38, p<0.001) and disability (EDSS,
rs=0.23, p=0.025). Differences between SPMS and controls
remained signiﬁcant after controlling for age (analysis of covari-
ance; deliberation times, p=0.003; risk-adjustment, p=0.007).
MRI measures
The MS group had signiﬁcantly smaller normalised GM
volumes (ie, atrophy) than controls in the anterior cingulate
(p<0.001), caudate (p<0.001) and occipital pole (p=0.001)
parcellations (table 4).
Compared with controls, the MS group had signiﬁcantly lower
DOC in the medial prefrontal (p<0.001), middle frontal gyrus
(p<0.001), anterior cingulate (p=0.002) and caudate parcella-
tions (p=0.003). On the other hand, the MS group showed
Table 2 Mean performance of the control and MS groups (and the MS subgroups) on each of the cognitive tests
Controls All MS RR SP PP
General cognitive function
Premorbid IQ (NART) 109.7 (10.3) 107.2 (11.0) 106.5 (11.3) 108.2 (9.2) 108.1 (12.7)
Current IQ (WAIS-III) 112.9 (15.0) 100.1 (15.8)*** 101.6 (15.2)*** 96.7 (17.3)*** 99.1 (16.1)**
Mood
Anxiety (HADS) 6.0 (4.1) 6.6 (4.0) 6.2 (3.8) 7.4 (4.5) 6.7 (4.3)
Depression (HADS) 2.9 (3.0) 6.1 (3.8)*** 5.5 (3.7)*** 7.1 (3.9)*** 6.7 (3.7)***
Executive function tests
Hayling sentence completion 6.1 (1.4) 5.1 (2.0)** 5.3 (2.1)* 5.1 (2.0)* 4.9 (2.1)*
Stroop time (seconds) 113.3 (22.9) 155.1 (66.9)*** 140.9 (55.5)** 175.0 (78.2)*** 178.2 (77.5)***
Information processing speed
Symbol digits modalities test (z-score) 0.56 (1.1) −0.97 (1.4)*** −0.78 (1.4)*** −1.3 (1.1)*** −1.2 (1.5)***
Memory tests
AMIPB immediate story recall 37.7 (8.5) 31.4 (10.4)** 32.9 (9.86)* 28.7 (10.5)*** 30.1 (11.4)**
AMIPB delayed story recall 35.7 (8.9) 28.7 (11.0)*** 30.5 (19.5)* 25.8 (11.0)*** 26.9 (11.7)**
AMIPB immediate figure recall 67.4 (11.5) 56.7 (14.8)*** 60.8 (12.9)** 51.3 (16.3)*** 49.1 (15.2)***
AMIPB delayed figure recall 67.0 (11.7) 55.1 (14.9)*** 59.3 (13.3)** 49.1 (14.4)*** 47.6 (16.2)***
Working memory
WAIS-III digit span (age-scaled score) 10.8 (2.9) 9.8 (2.9) 10.21 (3.1) 9.2 (2.6) 9.5 (3.2)
SDs are expressed in parentheses.
*p<0.05, **p<0.01, ***p<0.001 (comparisons are for the whole MS group against healthy controls or MS clinical subgroups against healthy controls).
AMIPB, Adult Memory and Information Processing Battery; HADS, Hospital Anxiety and Depression Scale; MS, multiple sclerosis; NART, National Adult Reading Test; PP, primary
progressive; RR, relapsing-remitting; WAIS-III, Wechsler Adult Intelligence Scale-III.
Table 3 Mean (SD) decision-making results for patients and controls, and for each clinical subtype
Controls All MS RR SP PP
Rational choices 0.93 (0.12) 0.89 (0.15) 0.90 (0.13) 0.89 (0.18) 0.89 (0.18)
Deliberation time 2782.84 (1319.37) 3885.69 (2392.50)** 3459.64 (1659.88)* 4529.58 (2249.24)*** 3561.48 (1190.32)
Amount bet 0.51 (0.15) 0.54 (0.14) 0.54 (0.13) 0.54 (0.17) 0.55 (0.13)
Impulsivity index 0.06 (0.19) 0.10 (0.18) 0.11 (0.13) 0.07 (0.17) 0.12 (0.20)
Risk adjustment index 1.39 (0.83) 0.93 (0.85)*** 0.97 (0.79) 0.66 (0.87)** 1.16 (0.99)
*p<0.05, **p<0.01, ***p<0.001 (comparisons are for the whole MS group against healthy controls or MS clinical subgroups against healthy controls, corrected for multiple
comparisons using Tukey’s post hoc tests).
MS, multiple sclerosis; PP, primary progressive; RR, relapsing-remitting; SP, secondary progressive.
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signiﬁcantly higher hippocampal DOC than controls (p=0.008).
There was no group difference in occipital pole DOC (p=0.169).
All group differences remained signiﬁcant after covarying for age,
gender and GM volume in each parcellation (p=0.046 to
<0.001), except for the anterior cingulate (p=0.055).
MRI measures in different MS subtypes
Multivariate ANOVAs revealed signiﬁcant group differences in
DOC in all parcellations except the occipital pole. Post hoc
Tukey’s tests showed signiﬁcantly lower DOC in the medial pre-
frontal parcellation in RRMS (p=0.006), SPMS (p=0.028) and
PPMS (p=0.030), in the middle frontal gyrus parcellation in
RRMS (p=0.001) and SPMS groups (p=0.003), in the anterior
cingulate in SPMS (p<0.001) and PPMS (p=0.009) groups,
and in the caudate in SPMS (p=0.001), compared with con-
trols. SPMS also showed lower DOC in the caudate than
patients with RRMS (p=0.031). No other differences reached
signiﬁcance (after correction for multiple comparisons).
Decision-making and MRI measures in people with MS
Deliberation time correlated with normalised GM volumes in
the caudate (r=−0.40, p<0.001) and with DOC in the medial
prefrontal (r=−0.27, p=0.008), and showed non-signiﬁcant
trends for correlations with DOC in the middle frontal gyrus
(r=−0.20, p=0.045), anterior cingulate (r=−0.25, p=0.012)
and caudate parcellations (r=−0.23, p=0.021). Risk adjustment
also showed a non-signiﬁcant trend for a correlation with hippo-
campal DOC (r=−0.23, p=0.024). Figure 2 shows parcellations
in which DOC correlated with decision-making components.
WM lesion volume correlated with deliberation time (r=0.28,
p=0.005) but not with risk adjustment.
In regression analyses, deliberation time was signiﬁcantly
related to DOC in the middle frontal gyrus (Exp(β): −0.202,
95% CI −4035.0 to −30.9; p=0.047) and medial prefrontal
parcellations (Exp(β): −0.265, 95% CI −4459.4 to −664.8;
p=0.009) and to normalised GM volume in the middle frontal
gyrus (Exp(β): −0.214, 95% CI −5779.2 to −223.3; p=0.035)
but only at trend level with the medial prefrontal parcellation
(p=0.06). Risk adjustment was associated with hippocampal
DOC (Exp(β): −0.226, 95% CI −2.8 to −0.3; p=0.019), but
not with GM volume in any parcellation (all p>0.09). Caudate
GM volume was a better predictor of deliberation time (Exp(β):
−0.409, 95% CI −10836.5 to −4370.8; p<0.001) than caudate
DOC (p=0.60).
Table 4 Mean (SD) MRI results for MS and control groups and for each clinical subtype
Controls All MS RR SP PP
Normalised GM volume
MFG 1.30 (0.15) 1.29 (0.14) 1.29 (0.12) 1.31 (0.15) 1.26 (0.13)
Medial prefrontal 0.37 (0.04) 0.35 (0.04) 0.36 (0.04) 0.35 (0.03) 0.36 (0.04)
Hippocampi 0.65 (0.04) 0.65 (0.04) 0.65 (0.05) 0.66 (0.04) 0.65 (0.05)
Anterior
Cingulate
0.89 (0.10) 0.83 (0.11)* 0.84 (0.09)* 0.80 (0.12)** 0.79 (0.14)**
Caudate 0.44 (0.04) 0.37 (0.08)*** 0.39 (0.07)** 0.34 (0.09)*** 0.38 (0.09)*
Occipital pole 1.25 (0.11) 1.16 (0.15)*** 1.16 (0.14)** 1.16 (0.17)* 1.19 (0.14)
Median white matter lesion volume (mL) – 9.78 (12.01) 4.30 (12.19) 8.59 (8.15) 6.36 (15.72)
DOC
MFG 3.097 (0.164) 2.963 (0.184)*** 2.963 (0.186)*** 2.940 (0.156)*** 2.995 (0.216)*
Medial prefrontal 3.277 (0.133) 3.157 (0.188)*** 3.162 (0.206)** 3.155 (0.169)** 3.141 (0.154)**
Hippocampi 2.290 (0.119) 2.352 (0.130)** 2.343 (0.134)* 2.377 (0.124)** 3.141 (0.154)
Anterior cingulate 3.011 (0.156) 2.892 (0.231)** 2.956 (0.173) 2.785 (0.260)*** 2.829 (0.292)**
Caudate 2.569 (0.181) 2.463 (0.196)** 2.505 (0.174) 2.383 (0.233)*** 2.439 (0.175)*
Occipital pole 3.153 (0.144) 3.110 (0.179) 3.114 (0.186) 3.093 (0.199) 3.121 (0.124)
Normalised GM volume is expressed as a percentage of total intracranial volume.
*p<0.05, **p<0.01, ***p<0.001 (comparisons are for the whole MS group against healthy controls or MS clinical subgroups against healthy controls).
DOC, diffusion orientational complexity; GM, grey matter; MFG, middle frontal gyrus; MS, multiple sclerosis; PP, primary progressive; RR, relapsing-remitting; SP, secondary progressive.
Figure 2 Parcellations in which
associations between decision-making
components and diffusion orientational
complexity (DOC) changes in patients
were found. Deliberation time
correlated with DOC in the middle
frontal parcellation and showed
non-signiﬁcant trends for correlations
with DOC (after correcting for multiple
comparisons) in the medial prefrontal,
caudate and anterior cingulate
parcellations (yellow). DOC in the
hippocampus (green) showed a
non-signiﬁcant trend for a correlation
with risk adjustment.
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DISCUSSION
Previous studies have shown impaired decision-making in
people with MS but have not clariﬁed which components are
most affected.1 2 4 11 In this work, we found that gauging risk
and adapting accordingly (risk adjustment), and slow deliber-
ation rather than impulsivity, are the primary features of
impaired decision-making in MS. We found no evidence for
increased impulsivity in MS, in keeping with studies using impli-
cit tests of impulsivity28 and Go/No-Go tasks.29 We found that
decision-making impairments were twice as common in people
with RR and PPMS than healthy controls, and almost four
times more common in people with SPMS. This is in line with
studies suggesting that decision-making impairments may be
more common in people with deﬁnite MS and some disability,
than those with clinically isolated syndromes, or early stable MS
with low levels of disability.2 30 We also found abnormal diffu-
sion MRI measures to be associated with decision-making
which, to the best of our knowledge, is the ﬁrst time that brain
structural abnormalities have been directly linked with decision-
making deﬁcits in people with MS.
In our study, impaired decision-making was most common in
SPMS, and similar in those with RR and PPMS. This is similar
to the results for cognitive impairment, which was associated
with decision-making deﬁcits, although the PPMS subgroup per-
formed as poorly as the SPMS on many cognitive tests. While
both risk adjustment and deliberation time correlated with
executive function, information processing speed on the SDMT
and memory, suggesting a role for cognitive disturbances in
decision-making difﬁculties in MS, decision-making was
impaired in people with and without cognitive impairment.
Anxiety also affected decision-making, increasing the number of
irrational-choices, which is in line with previous ﬁndings.31
Increased anxiety levels mediated the relationship between
amount bet on the CGT and cognitive variables, but did not
account for the associations between risk adjustment or deliber-
ation and memory, executive function or information processing
speed on the SDMT. The ﬁnding that memory, executive func-
tion and SDMT performance correlates with aspects of
decision-making highlights the point that lesions and other
forms of pathology in MS are likely to affect broad networks
(eg,32). The resulting aberrant connectivity among widely dis-
tributed brain regions may impact on networks involved in
decision-making and cognitive functions (as suggested by our
ﬁndings). Future work can help to unravel the impact of path-
ology on speciﬁc networks in MS.
We found that disease duration was associated with deliberation
time but not risk adjustment, suggesting that different decision-
making components may relate to, at least partly, independent
pathological processes. This is consistent with ﬁndings from
patients with traumatic brain injury, in whom correlations between
decision-making components and structural changes varied
between GM regions.23 In MS, neurodegeneration associated with
progression (leading to atrophy and microstructural changes) may
combine with focal cortical demyelination,33 particularly in outer
cortical regions,34 or metabolic changes in GM,35 to produce
greater decision-making deﬁcits than either alone.
We found increased MD in all GM parcellations, but reduced
FA only in the hippocampi and occipital poles (see online sup-
plementary material), and decreased DOC in all parcellations
except the hippocampi (where it was higher) and occipital poles
(no difference). Impaired risk adjustment has previously been
linked to focal insula lesions17 and to increased apparent diffu-
sion coefﬁcients in the thalamus and striatum in patients with
traumatic brain injury.23 We found correlations between risk
adjustment and memory in people with MS and controls, indi-
cating that poor memory (eg, for past outcomes) may inﬂuence
risk adjustment, which may explain the observed association
with hippocampal DOC. Deliberation time was associated with
DOC in the medial prefrontal cortex, middle frontal gyrus,
anterior cingulate and caudate. This indicates that relatively
widespread GM pathology can affect deliberation times.
Conﬁrming previous work,36 we also showed that WM lesions
are linked to slowed processing, which can impact on decision-
making times. Regional speciﬁcity was supported by the lack of
signiﬁcant correlations between occipital pole DOC and
decision-making components. While decision-making scores in
the MS group were mainly associated with DOC measures, and
only caudate volume correlated with decision-making, GM
atrophy explained signiﬁcant additional variance in regressions,
suggesting that DOC and GM atrophy provide complementary
information which is associated with functional changes. The
neural networks subserving decision-making, and in particular
the cortical areas involved, are well documented. Since the aim
of this study was to explore the relevance of cortical pathology
in decision-making it was advantageous to select these areas a
priori with the proviso of including another area as control
(occipital cortex). Future work can examine associations
between decision-making and regional GM density changes
throughout the brain and longitudinal studies can help deter-
mine whether reduced DOC and atrophy are related or inde-
pendent processes, and assess how these changes associate with
evolving decision-making and cognitive deﬁcits.
Some limitations to our study should be mentioned. In this
exploratory study we selected regions of interest based on pub-
lished evidence of impaired decision-making in different neuro-
logical and control populations and volumetric and diffusion
changes may also have been present in other GM areas.
Similarly we did not consider the contribution of normal
appearing WM pathology to decision-making and future studies
are needed to address these questions. The diffusion MRI mea-
sures were obtained at the highest clinically possible resolution
(2 mm isotropic), but given the thickness of the cortex (2–5 mm
thick) partial volume effects could have affected results. We
addressed this by using high-resolution T1-weighted scans to
segment brain tissues, a high threshold (50%) for classifying
voxels as GM and by building regression models with diffusion
and volumetric measures. Moreover, the regional volumetric
and diffusion differences make it unlikely that our results are
due to partial volume effects alone. Last, our progressive MS
subgroups were relatively small (26 SPMS and 18 PPMS). While
this represents the largest study of decision-making in people
with progressive MS to date, the differences we observed would
beneﬁt from replication in larger samples.
In summary, risk adjustment and speed of decision-making
were impaired in people with MS, with greater deﬁcits in SPMS
than RRMS and less severe impairments in PPMS than SPMS,
despite similar levels of physical disability. Decision-making
impairment was seen in people with MS who did not show
other cognitive deﬁcits and speciﬁc testing is required to detect
this clinically relevant impairment. In our MS group, abnormal-
ities in GM tissue microstructure (as demonstrated by DOC)
were more closely related to impairment in decision-making
than measures of GM atrophy.
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